XmAb^®5592

XmAb®5592 is currently undergoing preclinical development for the treatment of myeloma. XmAb®5592 is a humanized monoclonal antibody that targets the antigen HM1.24 and utilizes our proprietary Xencor XmAb^® Fc domain that enhances cytotoxic potency.